[A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia].

Abstract

Second-generation tyrosine kinase inhibitors (TKI 2) represent a recent important improvement in the treatment of Philadelphia positive leukemias. These agents are a suitable major option if resistance or significant imatinib intolerance occurs in chronic and accelerated phase CML. They are now introduced as first line therapy in chronic phase CML where they induce cytogenetic and molecular response rates never seen to date, which is promising for long-term survival. We propose here an analysis of the main current data available for the use of TKI 2 in CML.

• Authors: Marine Demarquet, Hélène Labussière-Wallet, Emmanuelle Nicolas-Virelizier, Franck-Emmanuel Nicolini
• Journal: Bulletin du cancer (Bull Cancer) Vol. 98 Issue 8 Pg. 859-66 (Aug 2011) ISSN: 1769-6917 [Electronic] France
• Vernacular Title: Une innovation thérapeutique : les inhibiteurs de tyrosine kinase de deuxième génération (ITK 2) dans le traitement de la LMC.
• PMID: 21816704 (Publication Type: Journal Article, Review)

Chemical References

• Aniline Compounds
• Antineoplastic Agents
• Nitriles
• Pyrimidines
• Quinolines
• Thiazoles
• bosutinib
• Protein-Tyrosine Kinases
• nilotinib
• Dasatinib

Topics

• Aniline Compounds (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Blast Crisis (drug therapy)
• Dasatinib
• Humans
• Leukemia, Myeloid, Accelerated Phase (drug therapy)
• Leukemia, Myeloid, Chronic-Phase (drug therapy)
• Nitriles (therapeutic use)
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Pyrimidines (therapeutic use)
• Quinolines (therapeutic use)
• Thiazoles (therapeutic use)